OneTest for Cancer
Protein-biomarker multi-cancer early detection, scored by AI
At-home multi-cancer blood test using protein tumor markers and AI scoring for annual risk tracking
Biomarkers
7-12 biomarkers (Standard/Premium)
Collection
At-home
Turnaround
Within 14 days
Price
$199
Physician reviewed
Yes
Membership
Not required
About
OneTest for Cancer is an at-home multi-cancer blood test from 20/20 BioLabs. Instead of reading circulating tumor DNA, it measures established protein tumor markers such as AFP, CEA, CA 19-9, Cyfra 21-1, PSA, CA125, and CA 15-3 on Roche IVD assays, then applies AI scoring to the biomarker pattern. Standard returns one overall risk score across 20+ cancer types; Premium adds individual risk readouts for eight common cancers. Results arrive through an online portal within 14 days and are intended to add another signal alongside standard cancer screening.
A licensed healthcare provider reviews the health questionnaire and authorizes the test before the kit ships. You can use your own physician at no OneTest charge, or add OneTest's $20 telemedicine authorization. The report is physician-reviewed when issued, but follow-up on elevated scores is intended to happen with your own doctor or care team.
What to Know
Signature approach
The test turns a protein-biomarker panel into a trendable cancer-risk score. Samples run in 20/20 BioLabs' CAP-accredited, CLIA-licensed lab, then the biomarker pattern is scored against an algorithm trained on roughly 28,000 asymptomatic adults followed for 12 years at Chang Gung Medical Hospital. The output is a 1-30 score tied to one-year cancer incidence, giving users and their clinicians a repeatable number to compare year over year.
What sets it apart
- Protein-biomarker method. OneTest uses established tumor-associated proteins on Roche IVD assays, which gives clinicians individual biomarker values as well as the composite score.
- Asymptomatic training cohort. The algorithm was trained on a real-world screening population of roughly 28,000 adults followed over 12 years.
- Annual trend tracking. The portal keeps prior results so users can compare biomarker values and risk scores over repeat tests.
- Occupational-health interest. Maryland fire departments received grant funding for OneTest screenings, showing early adoption in a high-risk workforce.
Before You Order
- Keep regular screening in place. Use this as an added signal alongside colonoscopy, mammography, low-dose CT, Pap testing, and clinician-directed care. - Pick the right tier. Standard gives one overall score. Premium costs more but adds individual risk readouts for eight common cancers. - Budget beyond the headline price. Collection and telemedicine authorization usually add $39 - $75 unless your own physician handles the order and draw. - Check state availability. Standard is not available in New York; Premium is not available in New York, Hawaii, or Alaska. - Use your doctor for follow-up. Elevated scores should be reviewed with your own physician, who can decide whether imaging, repeat labs, or specialist referral makes sense.
What's tested
Panel focus
What's included
Biomarker categories
Cancer Tumor Markers (Standard)
7 markersInflammatory Biomarkers (Premium add-on)
5 markersWhat’s not included
OneTest does not replace guideline-based screening such as colonoscopy, mammography, low-dose CT, or Pap testing. It is not designed for active cancer symptoms, current treatment, or recurrence monitoring. Follow-up imaging, biopsies, specialist visits, and downstream clinical care are not included in the test fee. Collection and telemedicine authorization are also separate checkout line items unless your own physician handles authorization.
Reference ranges methodology
Individual biomarkers are measured on Roche Cobas e411 immunoassay analyzers using Roche FDA-approved IVD detection kits. OneTest then evaluates the full biomarker pattern with an AI algorithm trained on real-world data from roughly 28,000 asymptomatic individuals followed for 12 years at Chang Gung Medical Hospital in Taiwan, later expanded with a 160,000-person Chinese hospital dataset. The result is a 1-30 risk score calibrated to observed one-year cancer incidence among people with similar biomarker patterns.
Pricing
Starting at
$199
The $199 Standard tier covers the lab assay: 7 protein biomarkers (5 for men, 6 for women), the composite AI risk score for 20+ cancer types, online portal access, and year-over-year result tracking. Collection is separate: $39 for at-home capillary self-collection or $55 for a partner-clinic draw. Telemedicine authorization is $20 unless your own physician signs the order.
Panel options
OneTest Standard
7 biomarkers
7 cancer biomarkers (5 male / 6 female), overall cancer risk score for 20+ cancer types, AI-powered analysis, online portal access, results within 14 days
OneTest Premium
12 biomarkers
All Standard biomarkers plus 5 inflammatory markers (12 total), individual risk assessment for 8 common cancer types, enhanced detection sensitivity, online portal access, results within 14 days
Expected first-year cost
$238/yr - $420/yr
In practiceReal-world pricing notes, add-ons, and coverage limits.
Standard is $199 and Premium is $345 before collection and authorization. Add $39 for at-home self-collection or $55 for a partner-clinic draw, plus $20 for telemedicine authorization if your own physician does not sign the order. Practical first-test pricing is about $238 - $258 for Standard and $384 - $420 for Premium. Both tiers are HSA eligible and self-pay, with no insurance coverage listed. Testing must be completed within 12 months of purchase, and annual retesting is the cadence the company recommends for trend tracking.
How it works
- 1
Order and authorize
Pick Standard or Premium, answer the health questionnaire, and route medical authorization through your own physician or OneTest's $20 telemedicine authorization.
- 2
Collect the sample
FedEx delivers the kit. Collect at home with the $39 capillary kit, or choose a $55 draw through a My One Medical Source or AnyLabTestNow partner clinic. No fasting is required. Ship back promptly: Standard samples must reach the lab within 72 hours, and Premium samples within 48 hours.
- 3
Read and share results
Within 14 days, the portal shows each biomarker value, the 1-30 risk score, and the Low, Mild, or Moderate tier. Reports are physician-reviewed when issued and are designed to be shared with your own doctor for any needed follow-up.
US availability
Availability
Not available in 3 US regions
Available in the other 47 US regions.
Exceptions
Alaska
Not available for Alaska residents (Premium only)
Hawaii
Not available for Hawaii residents (Premium only)
New York
Not available for New York residents (both Standard and Premium)
Frequently asked questions
What's the difference between Standard and Premium?
Standard runs 7 protein biomarkers and returns one overall risk score across 20+ cancer types. Premium adds five inflammatory markers for a 12-marker panel and returns individual risk readouts for eight common cancers: breast, colon, liver, lung, prostate, stomach, pancreas, and ovary. Premium samples also need to reach the lab within 48 hours, compared with 72 hours for Standard.
Does OneTest replace a colonoscopy or mammogram?
No. OneTest is designed to add another blood-based signal while standard screening continues on its normal cadence. Colonoscopy, mammography, low-dose CT, Pap testing, and clinician-directed follow-up still matter.
How is blood collected?
There are three options. The $39 at-home capillary kit collects a small sample without a phlebotomist. A partner-clinic draw through My One Medical Source or AnyLabTestNow costs $55 Your own physician can also perform the draw at no OneTest charge.
Is OneTest FDA-approved?
The individual biomarker assays use FDA-approved Roche IVD kits on Roche Cobas e411 analyzers in a CAP-accredited, CLIA-licensed lab. The composite AI risk score has not been FDA-cleared.
How often should someone retest?
The company recommends annual retesting, especially for adults 50+ or people with occupational or family-history risk. The score is calibrated to a 12-month window, and the portal keeps year-over-year biomarker values so trends are visible.
Other tests from 20/20 BioLabs
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.